Irene Motta

List of Publications by Year
in descending order

55 papers	1,605 citations	471509 17 h-index	315739 38 g-index
56 all docs	56 docs citations	56 times ranked	2277 citing authors

#	Article	IF	Citations
1	Reactivation of Developmentally Silenced Globin Genes by Forced Chromatin Looping. Cell, 2014, 158, 849-860.	28.9	370
2	Anemia in Clinical Practiceâ€"Definition and Classification: Does Hemoglobin Change With Aging?. Seminars in Hematology, 2015, 52, 261-269.	3.4	257
3	Elevated liver iron concentration is a marker of increased morbidity in patients with Â thalassemia intermedia. Haematologica, 2011, 96, 1605-1612.	3.5	153
4	Redefining thalassemia as a hypercoagulable state. Annals of the New York Academy of Sciences, 2010, 1202, 231-236.	3.8	78
5	Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers. Blood, 2016, 128, 1139-1143.	1.4	69
6	Anemia of chronic disease: A unique defect of iron recycling for many different chronic diseases. European Journal of Internal Medicine, 2014, 25, 12-17.	2.2	65
7	<scp>SARSâ€CoV</scp>â€2 infection in beta thalassemia: Preliminary data from the Italian experience. American Journal of Hematology, 2020, 95, E198-E199.	4.1	56
8	Anemia in elderly hospitalized patients: prevalence and clinical impact. Internal and Emergency Medicine, 2015, 10, 581-586.	2.0	53
9	Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation. Drugs, 2020, 80, 1053-1063.	10.9	49
10	The autophagy-activating kinase ULK1 mediates clearance of free Î±-globin in Î²-thalassemia. Science Translational Medicine, 2019, 11, .	12.4	44
11	Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with Î²-thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2012, 49, 136-139.	1.4	42
12	New therapeutic targets in transfusion-dependent and -independent thalassemia. Hematology American Society of Hematology Education Program, 2017, 2017, 278-283.	2.5	35
13	A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia. European Journal of Haematology, 2016, 96, 352-359.	2.2	34
14	Care of patients with hemoglobin disorders during the <scp>COVID</scp>â€19 pandemic: An overview of recommendations. American Journal of Hematology, 2020, 95, E208-E210.	4.1	24
15	Investigational drugs in phase I and phase II clinical trials for thalassemia. Expert Opinion on Investigational Drugs, 2017, 26, 793-802.	4.1	21
16	Diagnosis of chronic anaemia in gastrointestinal disorders: A guideline by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Society of Paediatric Gastroenterology Hepatology and Nutrition (SIGENP). Digestive and Liver Disease, 2019, 51, 471-483.	0.9	21
17	Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease. Molecular Genetics and Metabolism, 2018, 125, 64-72.	1.1	18
18	Management of age-associated medical complications in patients with Î²-thalassemia. Expert Review of Hematology, 2020, 13, 85-94.	2.2	18

#	Article	IF	Citations
19	CURING HEMOGLOBINOPATHIES: CHALLENGES AND ADVANCES OF CONVENTIONAL AND NEW GENE THERAPY APPROACHES.. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019067.	1.3	16
20	Differential Redox State and Iron Regulation in Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome and Coronavirus Disease 2019. Antioxidants, 2021, 10, 1460.	5.1	15
21	Clinical Complications and Their Management. Hematology/Oncology Clinics of North America, 2018, 32, 223-236.	2.2	14
22	Pharmacological Induction of Fetal Hemoglobin in Î²-Thalassemia and Sickle Cell Disease: An Updated Perspective. Pharmaceuticals, 2022, 15, 753.	3.8	14
23	Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. Liver International, 2020, 40, 3061-3070.	3.9	13
24	Innovative Treatments for Rare Anemias. HemaSphere, 2021, 5, e576.	2.7	13
25	Treatment with ferric carboxymaltose in stable patients with severe iron deficiency anemia in the emergency department. Internal and Emergency Medicine, 2020, 15, 629-634.	2.0	12
26	Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. Scientific Reports, 2021, 11, 2594.	3.3	12
27	Adrenal insufficiency: An emerging challenge in thalassemia?. American Journal of Hematology, 2017, 92, E119-E121.	4.1	11
28	Autoimmune Hemolytic Anemia as a Complication of Congenital Anemias. A Case Series and Review of the Literature. Journal of Clinical Medicine, 2021, 10, 3439.	2.4	8
29	Italian patients with hemoglobinopathies exhibit a 5â€fold increase in ageâ€standardized lethality due to SARSâ€CoVâ€2 infection. American Journal of Hematology, 2022, 97, .	4.1	7
30	Hyperferritinemia and diagnosis of type 1 Gaucher disease. American Journal of Hematology, 2020, 95, 570-576.	4.1	6
31	Thalassaemia is paradoxically associated with a reduced risk of inâ€hospital complications and mortality in COVIDâ€19: Data from an international registry. Journal of Cellular and Molecular Medicine, 2022, 26, 2520-2528.	3.6	6
32	A giant adrenal myelolipoma in a betaâ€thalassemia major patient: Does ineffective erythropoiesis play a role?. American Journal of Hematology, 2016, 91, 1281-1282.	4.1	5
33	ACQUIRED REFRACTORY IRON DEFICIENCY. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021028.	1.3	5
34	Î±-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study. Diagnostics, 2021, 11, 1628.	2.6	5
35	Redox Balance in Î²-Thalassemia and Sickle Cell Disease: A Love and Hate Relationship. Antioxidants, 2022, 11, 967.	5.1	5
36	ACTIVIN RECEPTOR LIGAND FOR THR TREATMENT OF BETA-THALASSEMIA: a SERENDIPITOUS DISCOVERY. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020075.	1.3	4

#	Article	IF	Citations
37	Migalastat Treatment in a Kidney-Transplanted Patient with Fabry Disease and N215S Mutation: The First Case Report. Pharmaceuticals, 2021, 14, 1304.	3.8	4
38	Deferasirox: an orphan drug for chronic iron overload in non-transfusion dependent thalassemia syndromes. Expert Opinion on Orphan Drugs, 2016, 4, 677-686.	0.8	2
39	Circulating cellâ€free DNA and ineffective erythropoiesis in nontransfusionâ€dependent Î²â€thalassemia. American Journal of Hematology, 2018, 93, E365-E368.	4.1	2
40	Iron deficiency from the standpoint of cardiac rehabilitation: novel therapeutic opportunities. Monaldi Archives for Chest Disease, 2019, 89, .	0.6	2
41	A holistic approach to iron chelation therapy in transfusionâ€dependent thalassemia patients with serum ferritin below 500â€‰Î¼g/L. American Journal of Hematology, 2020, 95, E230-E232.	4.1	2
42	Ferric carboxymaltose for sub-acute and chronic iron deficiency anemia in inherited platelet function defects. Internal and Emergency Medicine, 2021, 16, 505-507.	2.0	2
43	Management of chronic patients during the COVID-19 pandemic: the experience of a referral center for rare hematological disorders in the hardest-hit region in Italy. Annals of Hematology, 2021, 100, 2129-2131.	1.8	2
44	Epidemiological shift of glucose-6-phosphate dehydrogenase mutations in northern Italy in the last 15Âyears. Annals of Hematology, 2021, 100, 2683-2688.	1.8	2
45	2'-O-methoxyethyl splice-switching oligos correct splicing from IVS2-745 Î²-thalassemia patient cells restoring HbA production and chain rebalance. Haematologica, 2021, 106, 1433-1442.	3.5	2
46	Inhibition of Fibroblast Growth Factor-23 (FGF-23) Rescues Bone and Hematopoietic Stem Cell Niche Defects in Beta-Thalassemia, Uncovering the Missing Link between Hematopoiesis and Bone. Blood, 2021, 138, 572-572.	1.4	1
47	Inhibition of Fibroblast Growth Factor-23 (FGF-23) As a Novel Strategy to Target Bone and Hematopoietic Stem Cell Niche Defects in Beta-Thalassemia. Blood, 2020, 136, 2-2.	1.4	1
48	Splenomegaly: Dare to think rare. American Journal of Hematology, 2022, 97, 1259-1265.	4.1	1
49	Advancing the care of Î²-thalassaemia patients with novel therapies. Blood Transfusion, 2021, , .	0.4	1
50	Prolonged PT and aPTT in a patient with severe proteinuria. Internal and Emergency Medicine, 2013, 8, 611-614.	2.0	0
51	Thalassemia Is Paradoxically Associated with a Reduced Risk of In-Hospital Complications and Mortality in COVID-19: Data from an International Registry. SSRN Electronic Journal, 0, , .	0.4	0
52	Comparing Strategies to Reactivate Fetal Globin Expression for the Treatment of Beta-Globinopathies. Blood, 2014, 124, 333-333.	1.4	0
53	Finding and Treating Gaucher Disease Type 1 â€“ The Role of the Haematologist. European Oncology and Haematology, 2018, 14, 50.	0.0	0
54	Diagnostic Work-up of Pulmonary Hypertension in Non Transfusion Dependent Thalassemia Patients: Pathophysiologichal Mechanisms and Clinical Implications. Blood, 2020, 136, 21-22.	1.4	0

#	Article	IF	Citations
55	COVID 19 and Hemoglobinopathies: Update of the Italian Experience. Blood, 2020, 136, 17-18.	1.4	0